Clinical trial

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

NCT05132413

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-12-30

PhasePHASE3

Study timeline

Study start (estimated)2021-12-30Date precision: day

Registry last updated2021-11-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancerunresolved

Interventions

SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumabDRUG

Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatinDRUG

Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatinDRUG

Sponsors & collaborators

Suzhou Suncadia Biopharmaceuticals Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05132413 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.